 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | aprepitant topical (HT-001) / Hoth Therap
Phase classification: CLEER: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (clinicaltrials.gov) - Feb 15, 2024
P2, N=152, Recruiting, Sponsor: Hoth Therapeutics, Inc.
Phase classification: P2a --> P2
- | aprepitant topical (HT-001) / Hoth Therap
Trial initiation date: CLEER: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (clinicaltrials.gov) - Sep 11, 2023
P2a, N=152, Recruiting, Sponsor: Hoth Therapeutics, Inc.
Phase classification: P2a --> P2 Initiation date: Feb 2023 --> Jul 2023
- | aprepitant topical (HT-001) / Hoth Therap
Enrollment open: CLEER: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (clinicaltrials.gov) - Feb 9, 2023
P2a, N=152, Recruiting, Sponsor: Hoth Therapeutics, Inc.
Initiation date: Feb 2023 --> Jul 2023 Not yet recruiting --> Recruiting
- | aprepitant topical (HT-001) / Hoth Therap
New P2a trial: CLEER: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (clinicaltrials.gov) - Dec 7, 2022
P2a, N=152, Not yet recruiting, Sponsor: Hoth Therapeutics, Inc.